GI Cancer Biomarker Testing
Essential Biomarker Testing in GI Cancers

Released: August 18, 2021

Expiration: August 17, 2022

John L. Marshall
John L. Marshall, MD

Activity

Progress
1
Course Completed

In this episode, John L. Marshall, MD, discusses current molecular testing considerations in the treatment of patients with gastrointestinal tumors, including:

  • Current testing approaches, including IHC and PD-L1 assays and next-generation sequencing
  • Tumor agnostic testing: MSI, TMB, and NTRK fusion testing
  • Colon cancer: RAS, BRAF, and HER2
  • Gastric cancer: PD-L1, HER2, and more
  • Pancreatic cancer: BRCA
  • Biliary cancers: FGFR and IDH1
  • Liquid biopsies
  • When to test